Admittance Technologies Receives $1.99 Million from ETF

Admittance Technologies has received $1.99 million investment from the Texas Emerging Technology Fund.
The San Antonio-based company created the CardioVol technology platform to measure blood volume measurement using pacemaker to detect disease and treat patients with the devices.
“We are thankful for the investment from the ETF and the expertise that Startech provided during the process,” Dr. Marc Feldman, Founder and CEO of Admittance Technologies, said in a news release.
Dr. Feldman is a Professor of Medicine & Engineering at UT Health Science Center at San Antonio as well as the co-winner of the 2010 Chancellor’s Entrepreneurship Award for the University of Texas system.
Funding from the Texas Emerging Technology Fund allows researchers at the University of Texas Health Science Center at San Antonio to take “their ideas from concept to commercialization,” said David Weiss, vice president for research at the university.